We have almost nothing—no approved vaccine, no approved treatment.
The Bundibugyo strain is exceptionally rare, with only two prior documented outbreaks (2007, 2012) and no approved vaccines or treatments, unlike the more common Zaire strain. Cases have spread to major urban centers including Kinshasa (20M residents) and Kampala, with healthcare workers dying and evidence suggesting actual outbreak scale significantly exceeds official case counts.
- 8 confirmed cases, 336 suspected infections, 87 suspected deaths in DRC as of May 16
- Bundibugyo caused only 2 prior documented outbreaks (2007, 2012); current outbreak already exceeds both combined
- Cases confirmed in Kinshasa (20 million residents) and Kampala; at least 4 healthcare workers dead
- No approved vaccine or treatment exists for Bundibugyo; most existing tools target the Zaire strain
The WHO declared a Public Health Emergency of International Concern over a rare Bundibugyo Ebola outbreak in DRC and Uganda, with no approved vaccines or treatments available and suspected cases potentially far exceeding confirmed numbers.
On Sunday, the World Health Organization declared a global health emergency over an outbreak of Ebola caused by the Bundibugyo strain, a rare and dangerous variant spreading across the Democratic Republic of Congo and Uganda. The declaration marks the highest level of international alert, triggered by confirmed cases in two major cities—Kinshasa, home to roughly 20 million people, and Kampala, Uganda's capital—as well as evidence that the virus has circulated undetected for weeks before identification and may be far more widespread than official numbers suggest.
What makes this outbreak extraordinary, according to WHO Director-General Tedros Adhanom Ghebreyesus, is the absence of any approved vaccine or specific treatment for Bundibugyo, combined with persistent insecurity in eastern Congo and mounting uncertainty about the true scale of infection. As of May 16, the Democratic Republic of Congo had confirmed eight laboratory-verified cases, 336 suspected infections, and 87 suspected deaths in Ituri province. Uganda reported two confirmed cases in Kampala, including one death, both traced to travelers from Congo. The actual numbers are likely much higher. Initial testing found eight positive Ebola samples among just 13 specimens collected across different areas, and unexplained deaths and additional suspected cases continue to emerge in Ituri and neighboring North Kivu province.
Bundibugyo is one of the rarest known Ebola species to infect humans. It has caused only two documented outbreaks before this one: in Uganda in 2007 and in eastern Congo in 2012. Combined, those earlier outbreaks produced fewer cases than the current epidemic has already generated. Most existing vaccines and antibody treatments were developed against the Zaire strain, the more common and lethal variant that devastated West Africa a decade ago and killed more than 11,000 people. That earlier catastrophe consumed global attention and research resources, leaving Bundibugyo largely neglected. Susan McLellan, director of the biocontainment care unit at the University of Texas School of Medicine, noted that Zaire "captured all the attention, and for very good reasons." The consequence is stark: when Bundibugyo emerged, the world had no ready defenses.
The outbreak is concentrated in Ituri province near the Uganda border, particularly around Mongbwalu, a gold mining town where workers move constantly between remote camps and regional trading centers. This mobility, combined with the semi-urban nature of some transmission clusters, creates ideal conditions for rapid spread. At least four healthcare workers have died under circumstances consistent with viral hemorrhagic fever, raising alarm about transmission within clinics and hospitals—a pattern that echoes the devastating 2018-2019 Ebola epidemic in Congo's North Kivu and Ituri provinces. The WHO has drawn explicit parallels to that outbreak, warning that insecurity, population displacement, and mining-related movement will complicate containment efforts.
The WHO stopped short of declaring a "pandemic emergency," a new category created under revised international health regulations after COVID-19. Instead, it invoked the Public Health Emergency of International Concern designation, intended to mobilize international funding, coordinate response efforts, and focus global resources. This is the first such declaration since mpox was designated a global health emergency in 2024. The agency explicitly recommended against border closures or travel restrictions, arguing such measures are ineffective and risk driving people across unmonitored crossing points. Instead, it urged neighboring countries to strengthen surveillance, laboratory testing, and infection control while calling for urgent clinical trials of experimental vaccines and therapies.
Several potential treatments are under consideration, including monoclonal antibodies and remdesivir, an antiviral developed by Gilead Sciences, though none are approved specifically for Bundibugyo infection. Candidate vaccines from Oxford University and Moderna are also being evaluated. The timing of this emergency arrives as global health experts warn that cuts to U.S. foreign aid and epidemiological surveillance programs could weaken the world's capacity to respond to outbreaks in vulnerable regions. The outbreak's trajectory—spreading from remote mining areas into major urban centers, with healthcare workers among the dead and suspected cases far exceeding confirmed ones—suggests the true test of that capacity is only beginning.
Notable Quotes
This event is considered extraordinary, citing the absence of vaccines or treatments approved specifically for Bundibugyo, persistent insecurity in eastern Congo, and evidence the outbreak could be significantly larger than official case figures suggest.— WHO Director-General Tedros Adhanom Ghebreyesus
Zaire captured all the attention, and for very good reasons.— Susan McLellan, director of biocontainment care unit, University of Texas School of Medicine
The Hearth Conversation Another angle on the story
Why does it matter that this is Bundibugyo and not Zaire? Aren't they both Ebola?
They are, but the difference is everything right now. Zaire killed thousands in West Africa and got all the research money. We have vaccines for Zaire. For Bundibugyo, we have almost nothing—no approved vaccine, no approved treatment. We're starting from scratch.
So when they say the outbreak might be bigger than the numbers show, what does that actually mean on the ground?
It means people are dying of something that looks like Ebola—bleeding, organ failure—but they're not being tested or counted. In a remote mining area with no electricity, no lab capacity, no security, how would you even know? The virus could have been moving through those communities for weeks before anyone noticed.
The WHO said not to close borders. Why would countries want to anyway?
Fear. When people see Ebola, they panic and think isolation will protect them. But the WHO is right—it doesn't work. It just pushes people across unmarked borders where no one is watching. Better to test and track than to wall yourself off.
Healthcare workers are dying. What does that tell you?
That the virus is in hospitals now, not just in villages. That means it's spreading in places with more density, more contact, more opportunity to reach cities. It's the moment when an outbreak becomes harder to contain.
You mentioned mining. Why is that relevant?
Gold mining in that region is chaotic—workers move constantly between camps and towns, living in crowded conditions, no health infrastructure. It's the perfect environment for a virus to spread quietly and widely before anyone realizes what's happening.
What happens next?
They need to run clinical trials fast, get vaccines and treatments into arms, and hope the insecurity in eastern Congo doesn't make that impossible. And they need to do it without the world closing borders and making things worse.